{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T17:24:03Z","timestamp":1726421043475},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Orthopaedic Science"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jos.2017.04.011","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T20:15:54Z","timestamp":1495570554000},"page":"946-950","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The incidence of atypical femoral fractures in breast cancer patients with bone metastases who received bisphosphonate treatment"],"prefix":"10.1016","volume":"22","author":[{"given":"Eiji","family":"Nakata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsumi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shozo","family":"Osumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"58","key":"10.1016\/j.jos.2017.04.011_bib1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bone.2013.09.023","article-title":"Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review","author":"Eriksen","year":"2014","journal-title":"Bone"},{"issue":"16","key":"10.1016\/j.jos.2017.04.011_bib2","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2013the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.jos.2017.04.011_bib3","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.jos.2017.04.011_bib4","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"issue":"11","key":"10.1016\/j.jos.2017.04.011_bib5","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"issue":"12","key":"10.1016\/j.jos.2017.04.011_bib6","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/jbmr.1719","article-title":"Incidence of atypical nontraumatic diaphyseal fractures of the femur","volume":"27","author":"Dell","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"issue":"5","key":"10.1016\/j.jos.2017.04.011_bib7","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/jbmr.1550","article-title":"Incidence and demography of femur fractures with and without atypical features","volume":"27","author":"Feldstein","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"issue":"12","key":"10.1016\/j.jos.2017.04.011_bib8","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/archinternmed.2012.1796","article-title":"Increasing occurrence of atypical femoral fractures associated with bisphosphonate use","volume":"172","author":"Meier","year":"2012","journal-title":"Arch Intern Med"},{"issue":"18","key":"10.1016\/j.jos.2017.04.011_bib9","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft","volume":"364","author":"Schilcher","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.jos.2017.04.011_bib10","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/jbmr.1893","article-title":"Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis","volume":"28","author":"Gedmintas","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"issue":"1","key":"10.1016\/j.jos.2017.04.011_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00223-009-9263-5","article-title":"Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series","volume":"85","author":"Armamento-Villareal","year":"2009","journal-title":"Calcif Tissue Int"},{"issue":"64","key":"10.1016\/j.jos.2017.04.011_bib12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bone.2014.04.012","article-title":"A\u00a0large amount of microdamages in the cortical bone around fracture site in a patient of atypical femoral fracture after long-term bisphosphonate therapy","author":"Iwata","year":"2014","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.jos.2017.04.011_bib13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1359\/jbmr.2000.15.4.613","article-title":"Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib","volume":"15","author":"Mashiba","year":"2000","journal-title":"J\u00a0Bone Miner Res"},{"issue":"3","key":"10.1016\/j.jos.2017.04.011_bib14","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.jos.2017.04.011_bib15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/ans.12018","article-title":"Burden of bisphosphonate associated femoral fractures","volume":"83","author":"Shkolnikova","year":"2013","journal-title":"ANZ J Surg"},{"issue":"2","key":"10.1016\/j.jos.2017.04.011_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11420-008-9077-4","article-title":"Case report of spontaneous, nonspinal fractures in a multiple myeloma patient on long-term pamidronate and zoledronic acid","volume":"4","author":"Wernecke","year":"2008","journal-title":"HSS J"},{"issue":"4","key":"10.1016\/j.jos.2017.04.011_bib17","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00198-009-1012-0","article-title":"Bisphosphonate associated femoral fracture: implications for management in patients with malignancies","volume":"21","author":"Napoli","year":"2010","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.jos.2017.04.011_bib18","first-page":"1245","article-title":"Bisphosphonate-related atypical femoral fracture with bone metastasis of breast cancer: case report and review","volume":"34","author":"Hayashi","year":"2014","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.jos.2017.04.011_bib19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12282-011-0304-3","article-title":"A\u00a0case of femoral diaphyseal fracture after long-term treatment with zoledronic acid","volume":"22","author":"Ishizuna","year":"2015","journal-title":"Breast Cancer"},{"issue":"4","key":"10.1016\/j.jos.2017.04.011_bib20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2484\/rcr.v3i4.232","article-title":"Subtrochanteric femoral insufficiency fracture following bisphosphonate therapy for osseous metastases","volume":"3","author":"Bush","year":"2015","journal-title":"Radiol Case Rep"},{"issue":"3","key":"10.1016\/j.jos.2017.04.011_bib21","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.bone.2012.05.010","article-title":"Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy","volume":"51","author":"Chang","year":"2012","journal-title":"Bone"},{"issue":"13","key":"10.1016\/j.jos.2017.04.011_bib22","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2106\/JBJS.J.01199","article-title":"Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates","volume":"93","author":"Puhaindran","year":"2011","journal-title":"J\u00a0Bone Jt Surg Am"},{"issue":"1","key":"10.1016\/j.jos.2017.04.011_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research","volume":"29","author":"Shane","year":"2014","journal-title":"J\u00a0Bone Miner Res"},{"issue":"2","key":"10.1016\/j.jos.2017.04.011_bib24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ctrv.2013.09.015","article-title":"Time for more optimism in metastatic breast cancer?","volume":"40","author":"Senkus","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jos.2017.04.011_bib25","article-title":"Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis","author":"Ota","year":"2016","journal-title":"Breast Cancer"},{"issue":"8","key":"10.1016\/j.jos.2017.04.011_bib26","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1007\/s11999-012-2412-6","article-title":"Bisphosphonate-associated femur fractures have high complication rates with operative fixation","volume":"470","author":"Prasarn","year":"2012","journal-title":"Clin Orthop Relat Res"},{"issue":"5","key":"10.1016\/j.jos.2017.04.011_bib27","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1302\/0301-620X.92B5.22941","article-title":"A\u00a0rational approach to management of alendronate-related subtrochanteric fractures","volume":"92","author":"Das De","year":"2010","journal-title":"J\u00a0Bone Jt Surg Br"}],"container-title":["Journal of Orthopaedic Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0949265817301203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0949265817301203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T10:22:22Z","timestamp":1535797342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0949265817301203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0949265817301203"],"URL":"https:\/\/doi.org\/10.1016\/j.jos.2017.04.011","relation":{},"ISSN":["0949-2658"],"issn-type":[{"type":"print","value":"0949-2658"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The incidence of atypical femoral fractures in breast cancer patients with bone metastases who received bisphosphonate treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Orthopaedic Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jos.2017.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Japanese Orthopaedic Association. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}